Application Serial No. 10/633,653 Amendment dated September 20, 2006 Response to Official Action of June 20, 2006

RECEIVED CENTRAL FAX CENTER SEP 2 0 2006

## Amendments to the Claims:

The following listing of claims replaces all prior versions and listings of the claims in the application:

## **Listing of Claims:**

- 1. (Cancelled).
- 2. (New) A test kit for determining the binding capability of ligand to an analyte, which kit comprises
  - (a) a flow matrix comprising:
    - i) an application zone for analyte,
  - ii) a detection zone in which a biospecific affinity capturer reactant directed towards the analyte or towards an analyte-related reactant is firmly anchored, and
  - iii) a separation zone between the application zone for analyte and the detection zone, wherein the separation zone contains a ligand for which the binding capacity for the analyte is to be determined; and
  - b) optionally, an analytically detectable reactant having biospecific affinity to either the analyte or the capturer reactant.
- 3. (New) The test kit according to claim 2, wherein the flow matrix comprises a lateral flow matrix.
- 4. (New) The test kit according to claim 2, wherein transport channels of the flow matrix have capillary dimensions of a form and surface character that aqueous media is transportable therein by capillary forces.

2005/010

Application Serial No. 10/633,653 Amendment dated September 20, 2006 Response to Official Action of June 20, 2006

5. (New) The test kit according to claim 2, wherein the ligand exhibits one or

more positive and/or negative charges at the conditions under which the flow martix is to be

used.

09/20/2006 16:21 FAX

6. (New) The test kit according to claim 2, wherein the ligand is a biospecific

affinity reactant.

7. (New) The test kit according to claim 6, wherein the ligand is selected from

the group consisting of an antibody, an antigen and a hapten.

8. (New) The test kit according to claim 2, wherein the capturer reactant is

selected from the group consisting of an antibody, an antigen and a hapten.

9. (New) The test kit according to claim 2, wherein the kit includes the

analytically detectable reactant, and wherein the flow matrix comprises an application zone

for analytically detectable reactant located upstream of the detection zone.

10. (New) The test kit according to claim 9, wherein the analytically detectable

reactant is predeposited on the flow matrix at the application zone for analytically detectable

reactant.

11. (New) The test kit according to claim 9, wherein the ligand comprises one or

more library members of a library of compounds.

3

Application Serial No. 10/633,653 Amendment dated September 20, 2006 Response to Official Action of June 20, 2006

12. (New) The test kit according to claim 2, wherein the test kit includes the

analytically detectable reactant, and wherein the flow matrix comprises an application zone

for the analytically detectable reactant, located upstream of the separation zone and the

detection zone.

13. (New) The test kit according to claim 2, wherein the test kit includes the

analytically detectable reactant, and wherein the flow matrix comprises an application zone

for the analytically detectable reactant, located downstream of the separation zone but

upstream of the detection zone.

14. (New) The test kit according to claim 2, wherein the analytically detectable

reactant is predeposited on the flow matrix at a location upstream of the application zone for

analyte.

15. (New) The test kit according to claim 2, wherein the analytically detectable

reactant is predeposited on the flow matrix at a location downstream of the application zone

for analyte.

16. (New) The test kit according to claim 2, wherein the analytically detectable

reactant is predeposited on the flow matrix at the application zone for analyte.

17. (New) The test kit according to claim 2, wherein the ligand comprises one or

more library members of a library of compounds.

4